WuXi AppTec marks its 25th anniversary this year as a trusted partner to innovators worldwide. Over the past quarter century, the company’s integrated platform has reduced drug development timelines, helping advance breakthrough medicines for patients in the U.S. and around the globe.
Proven Global Partner Through Measurable Results
Since 2000, WuXi AppTec has provided integrated R&D and manufacturing solutions to innovators across the spectrum — from early-stage biotech to the world’s largest pharmaceutical companies. Its multi-jurisdictional regulatory expertise spans FDA, EMA, and NMPA guidelines, enabling faster, compliant market access for therapies around the world.
WuXi AppTec has contributed to reducing barriers to drug discovery, development, and manufacturing by investing in advanced technologies, expanding multi-region manufacturing capacity.
Integrated CRDMO Platform
WuXi AppTec’s Contract Research, Development, and Manufacturing Organization (CRDMO) model supports nearly 6,000 partners across 30+ countries through a distributed, resilient network of facilities. This integrated approach ensures that every stage — from early discovery to large-scale commercial manufacturing — advances seamlessly with efficiency, confidence, and world-class quality, backed by ISO/IEC 27001-certified information security management systems, customer-controlled access protocols, and annual third-party security audits.
With operations across Asia, Europe, and North America, the company meets the highest global regulatory standards — including zero critical FDA observations in 2024 — and engages proactively with health authorities worldwide.
Shaping the Future of Drug Modalities
In 2025, WuXi AppTec continued to expand its TIDES (oligonucleotide and peptide) manufacturing capacity, with its total reactor volume of Solid Phase Peptide Synthesizers expected to exceed 100,000L by end of 2025. These investments are helping accelerate the development of next-generation therapies in cancer, rare diseases, and other areas of urgent unmet medical need.
Commitment to Global Health and Sustainability
WuXi AppTec has achieved carbon neutrality across discovery operations and is committed to net-zero emissions by 2030. Compared to its 2020 baseline, the company has reduced water usage intensity by over 36% last year — reflecting its commitment to advancing science, enabling broader patient access, and driving measurable social impact worldwide.
Looking Forward
Building on 25 years as a trusted partner, WuXi AppTec will continue to advance breakthrough medicines through measurable improvements in speed, quality, and patient access — while maintaining the highest security and regulatory standards to serve patients worldwide.
Learn more at wuxiapptec.com.
For media inquiries, contact mediainquiries@wuxiapptec.com.
